EL7.AI
StocksMediumUpdated•Originally published 14 September 2026•Updated 14 September 2026•
2 min read

AstraZeneca’s Etcamah Combination Misses Phase III Goal in SERENA-4

Key Facts

1Etcamah plus palbociclib missed the Phase III SERENA-4 objective of a statistically significant progression-free-survival improvement despite producing a numerical improvement.
2The FDA granted Etcamah accelerated approval on September 4, 2026, 7 days before the SERENA-4 announcement, for a distinct use involving an ESR1 mutation during aromatase-inhibitor and CDK4/6-inhibitor therapy.
3Estimated median progression-free survival in the SERENA-6 data supporting FDA approval was 16 months versus 9.2 months, with confirmatory studies required.
4AZN closed on September 11, 2026, at $160.17 within a $158.13-$161.51 range, then fell about 3% after hours following the statement.

AstraZeneca said on September 11, 2026, that Etcamah combined with palbociclib missed the primary objective of the Phase III SERENA-4 trial: demonstrating a statistically significant improvement in progression-free survival among patients with advanced ER-positive, HER2-negative breast cancer who had received no systemic treatment for advanced disease. The combination nevertheless produced a numerical improvement, and the company will share full data later.

The randomized, double-blind SERENA-4 trial enrolled 1,371 adults and compared Etcamah plus palbociclib with anastrozole plus palbociclib. The outcome does not mean the treatment showed no effect; it means the progression-free-survival difference did not reach the prespecified statistical threshold in this population and regimen.

SERENA-4 addressed a different treatment setting from the use granted accelerated approval by the FDA on September 4, 2026, 7 days earlier. That approval covers Etcamah with a CDK4/6 inhibitor for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer when an ESR1 mutation is detected during aromatase-inhibitor and CDK4/6-inhibitor therapy.

The FDA's accelerated approval was based on SERENA-6, where estimated median progression-free survival was 16 months with Etcamah and a CDK4/6 inhibitor versus 9.2 months with an aromatase inhibitor and a CDK4/6 inhibitor. The clinical benefit of switching before imaging-confirmed progression remains unverified, so the agency required confirmatory studies.

AstraZeneca said the safety profile of Etcamah plus palbociclib in SERENA-4 was consistent with the known profiles of both medicines, with no new safety concerns. Detailed data will help assess the size of the numerical improvement, while the company continues the CAMBRIA-1 and CAMBRIA-2 early-breast-cancer trials involving about 10,000 patients.

AZN closed the September 11, 2026, session at $160.17 within a $158.13-$161.51 range. AstraZeneca issued its statement after the regular session ended, so the close did not reflect the result; the shares then fell about 3% in after-hours trading, indicating an initial negative reaction to the miss in this specific use.